Table 1.

Baseline Patient Characteristics

Characteristic	Arm 1 AUC = 16K No. (%)	Arm 2 AUC = 20K No. (%)	P value
No. of patients	49	48
Total busulfan dose (mg/kg), average (range)	9.7 (5.4-14.6)	12.5 (8.5-16.7)
Age at HCT in years, median (range)	57(18-75)	62 (41-75)	0.05
Age group
< 50 years	9(18)	6(13)
50-59 years	19 (39)	14 (29)
60-69 years	17 (35)	22 (46)
70-75 years	4(8)	6(13)
Sex
Male	36 (73)	28 (58)	0.14
Female	13 (27)	20 (42)
Race
White	36 (73)	41 (85)	0.21
Other	13 (27)	7 (15)
Diagnosis
Acute myeloid leukemia/Myelodysplastic syndrome	24 (49)	29 (60)	0.02
Complete remission	6	8
Relapsed (untreated/ hypoplastic marrow)	3	3
Primary induction failure	15	18
Chronic myeloid leukemia/ Myeloproliferative disorder	17 (35)	7 (15)
Chronic phase	3	1
Accelerated phase	1	1
Primary induction failure	10	3
Untreated/clonal evolution	3	2
Myeloma	5(10)	11(23)
Prior autologous HCT	4	8
Prior allogeneic HCT	-	1
Lymphoma	3(6)	0
Acute lymphoblastic leukemia	0	1(2)
No. of previous lines of chemotherapy, median (range)	1(0-10)	2(0-9)	0.36
Donor
HLA-matched unrelated	27 (55)	27 (56)	1.00
HLA-matched sibling	22 (45)	21 (44)
Graft source
PBPC	37 (76)	35 (73)	0.82
BM	12 (24)	13 (27)
Refined DRI			0.79
Low	2 (4)	1 (2)
Intermediate	28 (57)	25 (52)
High	17 (35)	18 (38)
Very high	2 (4)	4 (8)
HCT-CI
0-2	28 (57)	19 (40)	0.11
≥3	21 (43)	29 (60)

Abbreviations: AUC, area under the curve; BM, bone marrow; DRI, Disease Risk Index; HCT, hematopoietic cell transplantation; HCT-CI, Hematopoietic Cell Transplantation-Specific Comorbidity Index; HLA, human leukocyte antigen; PBPC, peripheral blood progenitor cells.